GSK statement on ACCC Federal Court judgment
The following statement from GSK Consumer Healthcare relates to proceedings in the Federal Court of Australia against GlaxoSmithKline Consumer Healthcare Australia Pty Ltd (GSK) alleging false or misleading representations in the marketing of Voltaren Osteo Gel 1% pain relief products.
We are pleased with today’s decision in relation to the revised Voltaren Osteo Gel 1% packaging that we supplied to the Australian market from March 2017 until the end of May 2018.
We take consumer law seriously. Last year, we admitted allegations in relation to certain historical packaging [that was supplied to the Australian market before March 2017] and some historical website content related to Voltaren Osteo Gel 1%.
It is important to clarify that certain actions taken by the ACCC in the recent years provided greater clarity around the expectations of companies marketing medicinal products. We responded to this clarification proactively when concerns were raised and made changes to Voltaren Osteo Gel 1% packaging to help ensure we continued to meet the expectations of regulators and consumers.
It would not be appropriate for us to comment further at this time.